Doorstead, a Full-Service Property Manager That Provides Cash-Flow Certainty to Residential Landlords with Its Upfront Rental Guarantee, Raises $12.5 Million in Series A Funding
19 Apr, 2021
– Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, announced today that it has raised $25m in a Series B financing led by existing investor, Morningside Ventures, and joined by new investors, Seligman Investments and Tao Capital Partners.
– The proceeds will support Apnimed’s ongoing development and commercialization plans.
– The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea (OSA), which is currently in late-stage Phase 2 clinical trials.
– AD109 combines a selective norepinephrine reuptake inhibitor (atomoxetine) with a novel new chemical entity (NCE) – a selective antimuscarinic (aroxybutynin).